Back

Ligachem Biosciences reports LCB43 results, plans IND filing within year

Verifying
  • Ligachem Biosciences released preclinical results for its multiple myeloma candidate LCB43.
  • 83% of patients required dose adjustments because of ocular toxicity in Blenrep's pivotal trial.
  • Ligachem Biosciences plans to file an IND application within the year.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Ligachem Biosciences reports LCB43 results, plans IND filing within year - CoinPost Terminal